Pulmonary fibrosis significantly increases the risk of severe pneumonitis (inflammation of lung tissue) among patients with lung cancer who were…
Articles by Patricia Inácio, PhD
Ofev (nintedanib) shows a similar ability to reduce lung function decline in patients with advanced idiopathic pulmonary fibrosis (IPF)…
BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and…
Pharmaxis’ first small molecule inhibitor of LOXL2 (lysyl oxidase like 2), an enzyme that promotes fibrosis in the lungs…
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a…
Low levels of the homeobox only protein x (HOPX) in lung samples from idiopathic pulmonary fibrosis (IPF) patients…
A gene therapy designed to fight pulmonary fibrosis (PF) by extending the lifespan of lung cells has been found safe…
A plant-based medicine called quercetin reversed pulmonary fibrosis in a mouse model likely by reducing the burden of growth-arrested…
The Arizona Biomedical Research Commission awarded a $750,000 grant to researchers at University of Arizona (UA) College of Medicine for their…
The American Lung Association’s Better Breathers Club is now extending its resources and support network to patients with pulmonary fibrosis (PF),…